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Brazil is the fifth largest country in the world and its present population, in excess of 190 million, 
is highly heterogeneous, as a result of centuries of admixture between Amerindians, Europeans, 
and Sub-Saharan Africans. The estimated individual proportions of biogeographical ancestry vary 
widely and continuously among Brazilians: most individuals, irrespective of self-identification as 
White, Brown or Black – the major categories of the Brazilian Census “race/color” system – have 
significant degrees of European and African ancestry, while a sizeable number display also 
Amerindian ancestry. These features have important pharmacogenetic (PGx) implications: first, 
extrapolation of PGx data from relatively well-defined ethnic groups is clearly not applicable to the 
majority of Brazilians; second, the frequency distribution of polymorphisms in pharmacogenes 
(e.g., CYP3A5, CYP2C9, GSTM1, ABCB1, GSTM3, VKORC, etc) varies continuously among 
Brazilians and is not captured by race/color self-identification; third, the intrinsic heterogeneity 
of the Brazilian population must be acknowledged in the design and interpretation of PGx 
studies in order to avoid spurious conclusions based on improper matching of study cohorts. 
The peculiarities of PGx in Brazilians are illustrated with data for different therapeutic groups, 
such as anticoagulants, HIV protease inhibitors and non-steroidal antinflammatory drugs, and the 
challenges and advantages created by population admixture for the study and implementation of 
PGx are discussed. PGx data for Amerindian groups and Brazilian-born, first-generation Japanese 
are presented to illustrate the rich diversity of the Brazilian population. Finally, I introduce the 
reader to the Brazilian Pharmacogenetic Network or Refargen1, a nation-wide consortium of 
research groups, with the mission to provide leadership in PGx research and education in Brazil, 
with a population health impact.
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databases, in consonance with either the first or the second 
models described by Pena (2007). However, both models are 
poor descriptors of admixed populations, since genetic admix-
ture is best  modeled as a continuous variable, consistent with 
the VMG paradigm (Suarez-Kurtz and Pena, 2006, 2007; Pena, 
2007). The individual uniqueness that is central to this paradigm 
implies that “each person must be treated as an individual… 
rather than as an exemplar of a race” (Patrinos, 2004) or in the 
words of McLeod (2007) “data from ethnic groups will not be 
as useful as analysis of individuals patients. While knowledge 
of ethnic differences may be relevant to much of the world’s 
population, its usefulness is significantly limited in situations 
of extensive genetic mixing”. With increasing global migration, 
admixture gains relevance as an additional challenge to the suc-
cessful worldwide implementation of PGx in clinical practice. 
From this perspective, the Brazilian population, with tri-hybrid 
ancestral roots in Amerindian, European and African groups, 
and five centuries of extensive interethnic mating, provides a 
valuable model for studying the impact of admixture on the 
conceptual development and clinical implementation of PGx-
informed prescription. In this review, I will initially offer a brief 
overview of the genetic diversity of present-day Brazilians and 
then move to the PGx arena to discuss data from our laboratory 
for different therapeutic groups and the PGx implications of the 
Brazilian population heterogeneity and admixture.
IntroductIon
“Pharmacogenetics deals with pharmacological responses and 
their modification by hereditary influences”. This definition, 
offered by Werner Kalow in the first book dedicated to phar-
macogenetics (Kalow, 1962), highlights the three pillars of 
this discipline: pharmacology, genetics, and human diversity. 
Pharmacogenetics has evolved greatly over the 50 years elapsed 
since Kalow’s book was published, was re-christened as phar-
macogenomics in the fashion of the “omics” revolution, but its 
conceptual development and praxis remain contingent upon a 
better understanding of human genomic diversity and its impact 
on drug pharmacokinetics and pharmacodynamics. In a recent 
review of the evolution and structure of human genetic diver-
sity, Pena (2007) discussed three models: The first, essentially 
typological, is based on the partition of humanity into races, 
visualized as being very different from each other, but inter-
nally homogeneous; the second, proposes a division into (con-
tinental) populations rather than races; the third, labeled the 
variable mosaic genome – VMG – paradigm, stresses individu-
ality rather than membership in population categories based 
on race, ethnicity or geographical origin. I would suggest that 
most pharmacogenetics/-genomics (PGx) studies continue to 
be performed, and the data analyzed, reported, and fed into 
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and African biogeographical ancestry were estimated using the 
software STRUCTURE (Pritchard et al., 2000). Each individual 
self-identified as white, brown, or black, according to the “race/
color” classification adopted by the Brazilian Census, which relies 
on self-perception of skin Color. The term Color is capitalized to 
call attention to its special meaning in the context of the Brazilian 
Census classification, Color (in Portuguese, “cor”) denoting the 
Brazilian equivalent of the English term “race”.
It is clear from Figure 1 that the individual proportions of 
Amerindian, European, and African ancestry, vary widely among 
Brazilians, and that most individuals have significant degrees of 
European and African ancestry, while a sizeable number display also 
Amerindian ancestry. The average proportions of European ancestry 
decreased progressively from self-reported White (0.86, n = 100), to 
Brown (0.68, n = 100) and then to Black individuals (0.43, n = 100), 
whereas the opposite trend was observed with respect to African 
ancestry, which averaged 0.07, 0.24, and 0.50 in White, Brown, and 
Black persons, respectively. Amerindian ancestry was relatively con-
stant across the three Color groups, ranging from 0.07 and 0.09 
(Suarez-Kurtz et al., 2007a). Further analysis of these data is beyond 
the scope of this review, and herein I will focus on two features that 
are evident in Figure 1 and have important implications for PGx: 
First, European and African components together account for 0.93 
(SD 0.08) of the genetic diversity in this cohort, as compared to 0.07 
PGx and PoPulatIon dIversIty: BrazIl as a model case
Brazil is the fifth largest country in the world and occupies an area 
of 8.5 million km2. Its present population exceeds 190 million peo-
ple, who speak Portuguese, in contrast to all other Latin American 
nations in which Spanish is the official language. The language 
reflects the colonization of Brazil by the Portuguese, initiated in the 
year 1500. At that time, the indigenous population living in the area 
of what is now Brazil was estimated at ∼2.5 million (Ribeiro, 1995). 
The Portuguese–Amerindian admixture started soon after the arrival 
of the first colonizers. The slave trade of Sub-Saharan Africans, from 
the middle of the sixteenth century until the late 1800s, provided the 
third major ancestral root of the Brazilian population. Centuries of 
admixture of Europeans – mainly Portuguese, but also Spaniards, 
Italians and Germans – Amerindians and Africans account for the 
heterogeneity and diversity of the present-day population of Brazil. 
The extent of admixture is well documented in a wealth of popu-
lation genetic studies in Brazilians (Salzano and Bortolini, 2002; 
Parra et al., 2003; Pena et al. 2009), and is illustrated in Figure 1 
with data from a cohort of 300 healthy, unrelated individuals liv-
ing in the city of Rio de Janeiro, in the Southeast region of Brazil 
(Suarez-Kurtz et al., 2007a). Individual DNA was genotyped with 
a panel of autosomal insertion/deletion (indel) polymorphisms, 
validated as ancestry-informative markers (Bastos-Rodrigues et al., 
2006) and the individual proportions of European, Amerindian 
FIgure 1 | Assignment of Brazilian samples to genetic clusters inferred 
using a panel of ancestry-informative markers and the program 
STruCTure. Data from 300 individuals, resident in Rio de Janeiro, 
self-identified as White, Brown, or Black, according to the Color classification 
adopted by the Brazilian Census. Each individual is represented by a vertical line, 
which is partitioned in three colored segments corresponding to the individual’s 
estimated membership proportion in the African (blue), Amerindian (green), and 
European (red) clusters. Data from Suarez-Kurtz et al. (2007a).
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genotyped in our lab. Mozambicans may be considered as  proxies 
of the African ancestors of Brazilians, since Mozambique, a former 
Portuguese colony in the southeast coast of Africa, was a source 
of slaves brought to Brazil in the nineteenth century. The agree-
ment between the model-estimated frequency of each CYP2C8 
polymorphism for Brazilians with 100% African ancestry and the 
observed frequency in Mozambicans is striking. However, we must 
caution that this result was not systematically observed for other 
pharmacogenes that we have studied, e.g., VKORC1 (Suarez-Kurtz 
et al., 2010a).
Assessment of the distribution of PGx polymorphisms accord-
ing to biogeographical ancestry is a novel approach, which I 
consider more appropriate for Brazilians, and most likely, other 
admixed populations of the Americas. Nevertheless, most PGx 
studies in Brazilians are designed, analyzed, and reported accord-
ing to racial/ethnic categories defined by different criteria and 
designated by a variety of labels. For example, the terms white, 
Caucasian, Caucasoid, European derived, Euro Brazilians or “of 
European descent” have been used to designate individuals who 
would, for the most part, self-identify as White according to the 
Brazilian Census. A similar situation is observed with respect to 
the Brown (reported as interethnic-admixed, mullato, intermedi-
ate, of mixed-ancestry, etc.) and Black (labeled as black, African-
derived, Afro- or African–Brazilians, etc) Color categories. The 
poor correlation between Color and ancestry in Brazilians (see 
above) casts a shadow of uncertainty over studies that have used 
only self-reported or investigator assessment of race/color with-
out genomic ancestry analysis. We are fully aware of this caveat, 
and by adopting the Census categorization in our studies do not 
expect to circumvent it. Quite on the contrary, we have recently 
shown that the frequency distribution of CYP2C8 and CYP2C9 
polymorphisms among self-identified White, Brown, and Black 
Brazilians varies significantly across different geographical regions 
(Suarez-Kurtz et al., 2010b). Thus, it makes little sense to extrapo-
late data on CYP2C8 and CYP2C9 polymorphisms from one or 
more Color strata recruited at a given geographical region (or city) 
to the ensemble of Brazilians. This is consistent with the notion 
that “people who are White, Brown, or Black in the northern part 
of Brazil are ancestrally quite unlike people who are White, Brown, 
or Black in the southern part of the Country” (Pena et al., 2009). 
Brazilian Census Color categories are, at best, poor proxies of 
biogeographical ancestry, a conclusion that has important PGx 
implications, since Brazilians may not fit into “race” or continental 
categories used to stratify participants of multinational PGx stud-
ies. For example, Brazilians self-identified as Pardo (Brown) could 
not be allocated into any of the four sub-groups (White, Asian, 
Black, or Mixed) of the International Warfarin Pharmacogenetic 
Consortium, a very important initiative that enrolled over 5,000 
patients from nine countries and four continents (IWPC, 2009). 
Also, Black Brazilians, with an estimated average proportion of 
African ancestry of 0.51 (Suarez-Kurtz et al., 2007), would not 
properly fit into the IWPC Black category, which included Africans 
and also African–Americans, the latter having average proportions 
of African ancestry around 0.80 (Parra, 2007). As a corollary, war-
farin dosing algorithms that have a “race” term defined by criteria 
prevalent in a given region or country (e.g., the United States OMB) 
are unlikely to be applicable worldwide, especially in extensively 
(0.08) for Amerindian ancestry. Consequently, European and African 
ancestry will have a considerably greater impact on the frequency 
of polymorphisms of PGx relevance, as compared to Amerindian 
ancestry. Second, the  individual  proportions of European and 
African ancestry vary over wide ranges, and most importantly, as 
a continuum across the Color categories of the Brazilian Census. 
Based on these two features, it is reasonable to anticipate that (i) the 
greater the difference in frequency of a given polymorphism between 
European and sub-Saharan African ancestral populations, the more 
likely the allele frequency will vary within the African–European 
admixed Brazilian population, and (ii) polymorphism frequency 
will vary continuously as a function of the individual proportions 
of European and/or African ancestry.
These predictions were verified for polymorphisms in several 
pharmacogenes (CYP3A5, CYP2C8, CYP2C9, CYP2C19, GSTM1, 
GSTT1 GSTM3, ABCB1, GNB3, and VKORC1), initially in indi-
viduals from Rio de Janeiro (Suarez-Kurtz et al., 2007a,b; Estrela 
et al., 2008a; Vargens et al., 2008) and more recently in a repre-
sentative cohort of the overall Brazilian population, which included 
1,100 self-identified White, Brown, and Black adults recruited at 
four different geographical regions (Suarez-Kurtz et al., 2010a,b). 
Figure 2 presents data for CYP2C8 to illustrate the procedure used 
to infer the statistical association between PGx polymorphisms and 
biogeographical ancestry. The plot shows that the individual odds 
of having the CYP2C8*2 allele increases, while the odds of having 
CYP2C8*3 and CYP2C8*4 decrease, as the proportion of African 
ancestry increases. Notably, the changes in allele probability are 
modeled as a continuum across the entire cohort, irrespective of 
self-identity with a Census Color category, consistent with the dis-
tribution of African ancestry among Brazilians shown in Figure 1. 
For comparison, the right column in Figure 2 shows the frequency 
of the CYP2C8 polymorphisms in a sample of 70 Mozambicans 
FIgure 2 | The plot on the left shows the frequency distribution of 
CYP2C8*1 (default, blue) *2 (red), *3 (orange), and *4 (red) alleles 
according to the estimated individual proportion of African ancestry in 
958 healthy, unrelated Brazilians. Non-linear logistic regression was applied 
to describe the association between biogeographical ancestry and frequency 
of CYP2C8 alleles. Data from Suarez-Kurtz et al. (2010b). The plot on the right 
shows the frequency of the CYP2C8 alleles in 70 healthy, unrelated 
Mozambicans (Suarez-Kurtz and Damasceno, unpublished).
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with Kaletra® at the Hospital Universitário Clementino Fraga Filho, 
Universidade Federal do Rio de Janeiro. With respect to ABCB1 
the study cohort was genotyped for the 1236C > T, 2677G > T/A, 
and 3435C > T SNPs. Multivariate regression analysis was applied 
to assess the influence of ABCB1 genotypes and haplotypes on 
the trough (pre-dose) concentrations of lopinavir and ritonavir in 
blood plasma, semen, and saliva (Estrela et al., 2009). We observed 
marked inter-individual variability in the concentrations of both 
protease inhibitors in the three matrices (e.g., a 27.5-fold range 
for lopinavir in plasma, Figure 3), but no association with ABCB1 
genotypes or haplotypes.
The goal of the CYP3A5 study in HIV-infected men (Estrela 
et al., 2008b) was to examine whether the reported impact of the 
CYP3A5 genotype on the disposition of the HIV protease inhibi-
tor, saquinavir, administered as a single dose and with no ritona-
vir boosting to Tanzanian healthy individuals (Josephson et al., 
2007) prevailed under a natural clinical setting. Our data revealed 
no influence of the CYP3A5 genotype on the trough plasma con-
centration of lopinavir and ritonavir in HIV-infected males on 
a stable HAART regimen. We ascribed the apparent discrepancy 
between our results (Estrela et al., 2008b) and those of Josephson 
et al. (2007) to ritonavir boosting, which was thought to occlude 
any pharmacokinetic consequences of functional polymorphisms 
in the CYP3A5 gene. Together, the two studies describe comple-
mentary steps towards the implementation of PGx in clinical 
practice, namely the discovery of association(s) between genetic 
polymorphisms and pharmacological traits under specific experi-
mental conditions, followed by examination of the impact of the 
association(s) in the targeted patient populations, studied in the 
relevant clinical setting.
Human immunodeficiency virus protease inhibitors have been 
recently reported to be substrates of the SLCO1B1/OATP1 drug 
transporter, and a SNP (521T > C) in the SLCO1B1 gene was asso-
ciated with plasma levels of lopinavir in HIV-infected individuals 
admixed populations, such as Brazilians. On a broader perspec-
tive, one may ask whether the global population diversity may be 
captured by inserting “race” terms in PGx algorithms that are suf-
ficiently “friendly” to be adopted by the practicing prescriber?
PGx studIes In BrazIlIans
The population diversity of Brazil implies that extrapolation of 
data derived from relatively well-defined ethnic groups is clearly 
not applicable to the majority of Brazilians (Suarez-Kurtz, 2008a,b). 
Only recently, recognition of this fact translated into PGx research 
on the clinical response to prescribed drugs. By comparison, much 
more information has accumulated over the last 15 years on genetic 
variation in metabolic pathways for environmental pro- carcinogens 
and its impact on cancer risk in Brazilians. Furthermore, various 
PGx targets such as alpha- and beta-adrenergic receptors, dopamine 
and 5HT receptors, components of the renin–angiotensin system, 
vascular endothelial growth factor and methylenetetrahydrofolate 
reductase have been the object of studies of disease susceptibility and 
phenotypes, rather than drug response in a clinical setting (Suarez-
Kurtz and Pena, 2007). Nevertheless, a few academic groups have 
conducted important PGx research on different therapeutic classes 
in the Brazilian population. Space limitations do not allow for a 
comprehensive review (and referencing) of all published PGx clini-
cal trials in Brazilians, but I would like to highlight the contribution 
of a few distinct groups in this area, before presenting an overview 
of our own studies. Mara Hutz et al. (Universidade Federal do Rio 
Grande do Sul) investigated the impact of genetic polymorphisms 
on the efficacy and toxicity of HMG-CoA reductase inhibitors 
(“statins”) in hypercholesterolemia (Hutz and Fiegenbaum, 2008), 
on the effects of methylphenidate in attention-deficit/hyperactivity 
disorders (Kieling et al., 2010), and on the efficacy of clozapine in 
schizophrenic patients (Kohlrausch et al., 2008). Rosario Hirata 
et al. (Universidade de São Paulo, USP) explored genetic determi-
nants of the lipid lowering effect of atorvastatin (Rodrigues et al., 
2007) and the impact of statins on the expression of ABC drug 
transporters and CYP3A drug metabolizing enzymes (Rebecchi 
et al., 2009). José-Eduardo Tanus-Santos (USP) examined the influ-
ence of polymorphisms in the endothelial nitric oxide synthase 
gene on the therapeutic drug response in gestational hypertension 
and preeclampsia (Sandrim et al., 2010) and on the atorvastatin-
induced changes in blood nitrite levels and erythrocyte membrane 
fluidity (Nagassaki et al., 2009).
PharmacokInetIcs of antIretrovIrals
The Brazilian public health system pioneered, in the early 1990´s, 
the universal access to HIV medications free of charge to all citizens 
who need it2. Ritonavir-boosted lopinavir formulations are fre-
quently included in highly active antiretroviral therapy (HAART) 
regimens for HIV infection. Both drugs are HIV protease inhibi-
tors, but ritonavir at the doses used in co-formulations with lopi-
navir, serves the purpose of inhibiting CYP3A drug metabolizing 
enzymes, thereby increasing (“boosting”) the exposure to lopinavir, 
a CYP3A substrate. We studied the impact of polymorphisms in the 
ABCB1, CYP3A5, and SLCO1B1 genes on the pharmacokinetics of 
lopinavir and ritonavir in HIV-infected men under stable treatment 
FIgure 3 | Intra-individual variability of lopinavir pharmacokinetics. The 
plot shows the trough (pre-dose) concentration of lopinavir in the plasma of 99 
HIV-infected males, under stable HAART treatment including two daily doses 
of lopinavir (400 mg) and ritonavir (100 mg). Each data point corresponds to 
one individual. Data from Estrela et al. (2009).
2www.aids.gov.br
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(Perini et al., 2005). The results verified our  hypothesis by show-
ing significant differences in TxB
2
 production between either 
CYP2C9*1/*2 or CYP2C9*1/*3 genotypes and CYP2C9*1/*1. 
The ANOVA R2 (coefficient of variation) among the three geno-
types, indicated that 78% of the inter-individual variability may 
be explained by the CYP2C9 polymorphisms examined, namely 
CYP2C9*2 and CYP2C9*3. This is a remarkable example of PGx 
modulation, as there are not many instances of such a large contri-
bution of genetic polymorphisms to the inter-individual variability 
of pharmacodynamic phenotypes.
The piroxicam bioequivalence trial disclosed one individual 
who displayed a unique pharmacokinetic profile, such that his 
plasma piroxicam concentration 13 days after the administration 
of a single drug dose remained at 70% of the peak concentra-
tion measured at 2 h (estimated half-life of elimination, 500 h). 
Nevertheless, no adverse effects were observed or reported by 
the individual. After a 6-month washout, when piroxicam was 
no longer detected in his plasma, this individual was re-exposed 
to a single piroxicam dose, and blood samples were collected for 
120 days for CYP2C9 genotyping, measurements of piroxicam 
plasma concentrations and assessment of the activity of COX-1 
and COX-2 – the pharmacodynamic targets of NSAIDs – through 
the ex vivo formation of TBX
2
 and prostaglandin E2, respectively 
(Perini and Suarez-Kurtz, 2006). The individual was genotyped 
as CYP2C9*3/*3, an extremely rare genotype in Brazilians, which 
encodes a non-functional CYP2C9 isoform. The impact of this 
genotype was remarkable: the effects on pharmacokinetic param-
eters observed with the first dose were reproduced and the pharma-
codynamic analyses showed that COX-2 activity was maintained 
below 50% of its control value for more than one month and that 
COX-1 was below 20% of its control value for more than 2 months 
after the single piroxicam dose! Again, no adverse effects were 
observed. We speculated on the potential advantages conferred by 
the PGx polymorphisms associated with impaired drug metabo-
lism for long-term strategies in disease prevention and treatment 
(Perini and Suarez-Kurtz, 2006).
(Hartkoorn et al., 2010). The availability of plasma concentration 
data for lopinavir and ritonavir from our cohort of HIV-infected 
men under stable HAART, provided the opportunity for seek-
ing independent confirmation of these results and for extending 
these observations in two directions: first, by examining two other 
SLCO1B1 SNPs, (388A > G, 463C > A) and second, by exploring the 
association of the SLCO1B1 polymorphisms with ritonavir plasma 
concentrations (Kohlrausch et al., 2010). Our results confirmed 
that carriers of the 521C allele display significantly higher lopinavir 
(but not ritonavir) plasma concentrations relative to the wild-type 
TT genotype. There was no significant effect of either 388A > G or 
463C > A SNPs on lopinavir or ritonavir plasma concentrations. 
Reduced OATP-mediated uptake of lopinavir by the hepatocytes in 
carriers of the SLCO1B1 521C allele was thought to account for the 
increased plasma levels of lopinavir. The clinical usefulness of this 
observation is uncertain at present, in view of both the extensive 
overlap of the trough concentrations of lopinavir in the plasma 
across the three 521T > C genotypes and the low prevalence (<5%) 
of the homozygous variant genotype (521CC) in most populations. 
Further studies to confirm the importance of SLCO1B1 polymor-
phisms in lopinavir pharmacokinetics are warranted.
PharmacokInetIcs and PharmacodynamIcs of nsaIds
The implementation of regulatory legislation for generic drugs 
in Brazil, in the late 1990s provided an impetus for bioequiva-
lence studies. The relatively large number of samples collected 
from healthy subjects under the rigorously controlled conditions 
of bioequivalence trials offer a favorable experimental setting for 
assessing the influence of genetic polymorphisms on pharmacoki-
netic parameters. Our group explored this opportunity with respect 
to the impact of CYP2C9 polymorphisms on the pharmacokinetics 
and pharmacodynamics of the non-steroidal anti-inflammatory 
drugs (NSAIDs), tenoxicam, and piroxicam (Vianna-Jorge et al., 
2004; Perini et al., 2005). These were “gene-candidate” studies, the 
choice of CYP2C9 being based on previous knowledge that the 
encoded cytochrome P-450 (CYP) enzyme, CYP2C9, provides the 
major metabolic pathway for the inactivation of both piroxicam 
and tenoxicam. The polymorphisms investigated, CYP2C9*2 and 
CYP2C9*3, encode CYP2C9 isoenzymes with reduced metabolic 
activity towards these NSAIDs. The results of the pharmacokinetic 
analyses are shown in Table 1.
The CYP2C9 genotypes had no influence on the peak concen-
tration of either drug in plasma (C
max
). By contrast, the plasma 
concentration–time curve from zero to infinity (AUCinf), a meas-
ure of drug exposure, was significantly greater in CYP2C9*1/*2 or 
*1/*3 heterozygous, as compared to wild-type homozygous subjects 
(CYP2C9*1/*1). This effect was associated with, and explained by 
the significantly lower oral clearance (corrected for body weight, 
CL/F
cor
) of either NSAID in heterozygous carriers of the CYP2C9*2 
or *3 alleles, compared to wild-type homozygous subjects.
The piroxicam study was extended to include a pharmacody-
namic parameter, namely the ex vivo production of thromboxane 
B2 (TxB
2
), catalyzed by cyclo-oxygenase 1 (COX-1), a distinct target 
of NSAIDs. Our work hypothesis was that inhibition of COX-1 by 
piroxicam would be greater in carriers of the defective CYP2C9*2 
and CYP2C9*3 alleles, because of the increased exposure to piroxi-
cam in these individuals, as compared to wild-type homozygous 
Table 1 | Impact of CYP2C9 polymorphisms on pharmacokinetic 
parameters for single doses of piroxicam and tenoxicam in healthy 
Brazilian individuals.
 CYP2C9 ANOVA 
Drug/parameter genotypes P valuea
 *1/*1 *1/*2 *1/*3 
TeNOxICAm (20 mg p.o.)
Cmax (μg mL
−1) 2.7 ± 0.9 2.7 ± 0.6 2.6 ± 0.8 0.964
AUCinf (μg mL
−1 h) 190 ± 48 261 ± 14b 335 ± 126b 0.004
CL/Fcor (mL h
−1 kg−1) 1.8 ± 0.4 1.2 ± 0.1b 1.1 ± 0.4b 0.011
PIrOxICAm (20 mg p.o.)
Cmax (μg mL
−1) 2.5 ± 0.7 2.2 ± 0.5 2.4 ± 0.4 0.44
AUCinf (μg mL
−1 h) 154 ± 37 256 ± 97b 259 ± 95b 0.0001
CL/Fcor (mL h
−1 kg−1) 2.0 ± 0.5 1.3 ± 0.4b 1.3 ± 0.4b 0.0001
Data are given as mean ± S.D. aANOVA performed on log-transformed values, 
for comparison across the three genotypes. bP < 0.05 for pair-wise comparisons 
between CYP2C9*1/*2 or CYP2C9*1/*3 versus CYP2C9*1/*1 (Student– 
Newman–Keuls test).
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for  prediction of the  appropriate warfarin dose for each patient. 
As shown in Figure 4, the VKORC1 3673G > A genotype proved 
to be the most important predictor in our model, with a partial 
R2 value of 23.8%, followed by the number of copies of variant 
CYP2C9 alleles (R2 = 6.9%) and by co-treatment with amiodarone 
(R2 = 5.6%). Body weight, therapeutic indication for the use of 
warfarin, age, and co-treatment with simvastatin were the other 
covariates associated with warfarin dose requirement. A dosing 
algorithm including all these covariates explained 51% of the vari-
ance in warfarin dose requirement in our study cohort.
We extended our studies on the INCL cohort to explore the asso-
ciation of other variables with warfarin dose requirements (Suarez-
Kurtz et al., 2009), and reported that the inclusion of INR/dose 
as a covariate in regression modeling of the stable warfarin dose 
leads to a novel algorithm with greater predictive power (R2 = 60%; 
Figure 5). The most informative model retained the same covariates 
previously identified as associated with stable warfarin weekly dose 
in this cohort (age, weight, treatment indication, co-medication 
with amiodarone, or simvastatin, VKORC1 and CYP2C9 genotypes) 
but included also an INR/dose term. A distinct feature of the novel 
algorithm is that the individual INR/dose term does not represent a 
fixed time point after starting warfarin therapy, but rather the first 
measurement taken after admission of the patients in the antico-
agulant unit. This feature is potentially useful for patients under 
continuous warfarin treatment, who had not reached stable dosing 
despite repeated dose adjustments.
WarfarIn dosInG alGorIthms for BrazIlIans
Warfarin combines several characteristics that make it a model 
target for individualized drug therapy: (i) it is the most com-
monly prescribed oral anticoagulant in Brazil and worldwide, (ii) 
there is large inter-individual variation in the required dosage, 
(iii) its therapeutic index is narrow and incorrect dosage, espe-
cially during the initial phase of treatment, carries a high risk of 
 bleeding or failure to prevent thromboembolism, and (iv) a reliable 
biomarker, the international normalized ratio (INR), is available 
for quantifying warfarin’s anticoagulant effect. Polymorphisms in 
two genes, namely CYP2C9 and VKORC1, have been repeatedly 
found to associate with the clinical response to warfarin. CYP2C9 
encodes CYP2C9, the primary metabolic route for the disposition 
of S-warfarin, the most active isomer of clinically used racemic 
warfarin. The polymorphic VKORC1 gene codifies VKORC1 the 
molecular target of coumarin anticoagulants. In collaboration 
with the Instituto Nacional de Cardiologia Laranjeiras (INCL), 
a reference cardiology hospital of the Brazilian Public Health 
System located in Rio de Janeiro, we assessed the contribution 
of CYP2C9 and VKORC1 polymorphisms, and of demographic 
and clinical variables to the inter-individual variability in warfarin 
dose requirement for stable anticoagulation, defined as three suc-
cessive INR readings in the 2–3.5 range (Perini et al., 2008a). The 
warfarin dose required for stable anticoagulation varied from 3 to 
75 mg/week, i.e., a 25-fold inter-individual variability! Multivariate 
regression modeling was applied to develop a dosing algorithm 
FIgure 4 | Influence of genetic and non-genetic factors on the warfarin 
dose requirement for stable anticoagulation in 390 patients from the 
INCL, rio de Janeiro. Multivariate regression modeling was applied to 
identify the factors (covariates) that associate significantly with the individual 
warfarin weekly dose requirement. The relative contribution of each covariate 
to the final model is expressed by the partial R2 statistics (abscissa), which 
measures the degree of association between two random variables, with the 
effect of a set of controlling random variables removed. The higher the R2 
value, the greater the contribution of the covariate to the model. Data from 
Perini et al. (2008).
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individuals with heterogeneous genetic ancestry, under the same 
environmental conditions. A distinct feature of a PGx algorithms 
derived from our patient cohort is the ability to predict equally 
well the warfarin dose requirement in White and Black patients, 
in marked contrast with the poorer outcome of several warfarin 
dosing algorithms in blacks, notably African–Americans, as com-
pared to white patients (Gage et al., 2008). Third, the non-genetic 
covariates of our dosing algorithms are readily available in the 
patient medical record, whereas the genetic covariates, namely, the 
CYP2C9 and VKORC1 3673G > A genotypes, can be determined 
in a time frame  compatible with the urgency of starting warfarin 
administration to many patients. However, we also recognize that 
our studies have limitations, most of which are common to studies 
of similar design performed in other populations. First, by being 
retrospective, the associations and dosing algorithm described in 
our studies must be prospectively tested in an appropriately large 
cohort. Second, we did not assess the impact of the algorithms 
on the clinical response to warfarin but instead used the INR as 
a surrogate for it. Third, by explaining 51–60% of the variance in 
warfarin dosing, our algorithms leave 40–50% of this variance to be 
accounted for by other variables, whether genetic or non-genetic. 
Finally, our algorithms, developed for a heterogeneous and admixed 
population of a large Brazilian city, may not be applicable to other 
population groups.
studIes In amerIndIan GrouPs lIvInG In BrazIl
Native American (Amerindian) populations are poorly represented 
in PGx research and PGx databases (reviewed by Jaja et al., 2008). 
The extant Amerindian population of Brazil is very diverse, con-
sisting of more than 227 ethnic groups speaking more than 180 
languages4. This diversity is reflected in the frequency of polymor-
phisms in genes encoding drug metabolizing enzymes and drug 
targets (reviewed in Suarez-Kurtz and Pena, 2007). In collabora-
tion with Maria Luiza Petzl-Erler et al. from Universidade Federal 
do Paraná we assessed the distribution of four SNPs in VKORC1 
in three endogamous Amerindian populations, namely Guarani-
Kaiowá, Guarani-Ñandeva, and Kaingang, living in indigenous res-
ervation areas in the South and Center-West regions of Brazil (Perini 
et al., 2008b). Despite living side by side for centuries, the Guarani 
(Tupi-Guarani linguistic family) and the Kaingang (Gê-speaking 
people) maintain their cultural and linguistic distinctiveness, which 
is paralleled by substantial genetic distance between them. Our 
results indicated that the VKORC1 5808T > G SNP was absent or 
rare (<3%), whereas 3673G > A, 6853G > C and 9041G > A were 
frequent (34–63%) in the three Amerindian populations. No differ-
ence was detected in VKORC1 allele or genotype frequency between 
the two Guarani populations, whereas significant differences were 
observed between Kaingang and Guarani. The data disclosed a 
uniqueness of the frequency distribution of the VKORC1 SNPs 
in the Guarani and Kaingang, compared to Asian, African, and 
European populations. However, in view of the vast inter-popu-
lational diversity among Amerindians, these results should not be 
interpreted as representative of other extant Amerindian peoples. 
Our observation that 40% of Kaingang and 60% of Guarani have 
VKORC1 haplotypes that include the variant 3673A allele associated 
In a recently published study (Perini et al., 2010) we investigated 
the association between warfarin dose requirement and a polymor-
phism in CYP4F2, namely, rs2108622 C > T (V33M). Biological 
plausibility for this association was provided by the evidence that 
CYP4F2 is a vitamin K1 oxidase and carriers of the CYP4F2 33M 
allele are likely to have elevated hepatic levels of vitamin K1, requir-
ing higher warfarin doses (McDonald et al., 2009). Previous studies 
had reported controversial results regarding the contribution of 
the CYP4F2 rs2108622 to the warfarin dose requirement for stable 
anticoagulation, but had one common feature: the enrolled patients 
were exclusively or predominantly (>90%) white, of European 
descent. The allele frequency of rs2108622 differs markedly among 
populations, being lower in sub-Saharan Africans and African–
Americans (0–9%) as compared with Europeans and white North 
Americans (17–33%)3. From a population perspective, it might be 
anticipated that rs2108622 will have a smaller influence, if any, on 
the warfarin dose requirements in black individuals. We explored 
this hypothesis in the INCL cohort, which included self-identified 
White, Brown, and Black individuals, and observed that addition of 
the rs2108622 genotype as a variable had only a marginal effect on 
the predictive power of the warfarin dosing algorithm previously 
derived from this patient cohort. We concluded that prospective 
CYP4F2 genotyping is not justified in Brazilians who are potential 
candidates for warfarin therapy (Perini et al., 2010).
Collectively, out studies on the PGx of warfarin in Brazilians 
have distinct strengths. First, they reflect real-life community 
prescribing and dispensing of warfarin in the context of a pub-
lic hospital in a developing country. Second, the recruitment of 
patients from the notoriously admixed and heterogeneous Brazilian 
population allowed for the investigation of PGx associations in 
FIgure 5 | relationship between warfarin weekly doses predicted by a 
multiple regression model (abscissa) and the stable doses actually taken 
by 390 patients (ordinate) from INCL, rio de Janeiro. The covariates in the 
dosing algorithm were age, weight, treatment indication, co-medication with 
amiodarone or simvastatin, VKORC1, and CYP2C9 genotypes and the first 
available INR reading for each patient. The identity line is traced. Data from 
Suarez-Kurtz et al. (2009).
3http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs = 2108622 4www.socioambiental.org/pib/index.html
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Brazilians: Impact of population 
admixture. Pharmacogenomics 9, 
267–276.
polymorphisms. Ann. Hum. Genet. 
70, 658–665.
Estrela, R. C. E., Ribeiro, F. S., Carvalho, 
R. S., Gregorio, S. P., Dias-Netto, E., 
Struchiner, C. J., and  Suarez-Kurtz, 
references
Bastos-Rodrigues, L., Pimenta, J. R., 
and Pena, S. D. J. (2006). The genetic 
structure of human populations stud-
ied through short insertion-deletion 
information on peoples that are excluded or  under- represented in 
clinical drug trials. For example, studies in Brazilians could fill in 
PGx information gaps, pertinent to Africans and Native Americans. 
A major challenge to pharmacogeneticists studying the Brazilian 
population is population stratification, which if not controlled for, 
will confound the outcomes of PGx association studies. Our stud-
ies have provided examples of how to control for this caveat, by 
combining ancestry-informative markers and appropriate statistical 
approaches. A distinct message that emerges from these studies is 
that race/color categorization does not capture the distribution of 
PGx polymorphisms among Brazilians, which is best modeled by 
continuous functions of the individual proportions of European and 
African ancestry, irrespective of self-identified Color. Recognition of 
this fact is important in the design and interpretation of PGx clini-
cal trials in Brazilians but does not imply that PGx-informed drug 
prescription requires investigation of individual ancestry. Rather, 
individual genotyping should be directed to PGx polymorphisms 
of proven clinical utility for the specific medical condition being 
treated, irrespective of biogeographical ancestry. Because of their 
tri-ancestral roots and extensive admixture, the vast majority of 
Brazilians will require PGx tests for polymorphisms that have been 
clinically validated in European, sub-Saharan African and, to a lesser 
extent, Amerindian populations. The CYP2C9 gene may be used as 
an example, in the context of warfarin dose requirement: variant 
alleles CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 occur in 
Africans but are rare or absent in Europeans, whereas the opposite 
is observed with respect to CYP2C9*2 and CYP2C9*3. Genotyping 
of the six polymorphisms could be justified in Brazilians and, 
most likely, African–Americans, but not Europeans, in whom only 
CYP2C9*2 and CYP2C9*3 genotyping might be adequate for pre-
dicting the CYP2C9 phenotype.
Personalized drug therapy, the promise of pharmacogenom-
ics, must be based on the recognition of the inherent genetic 
individuality. This notion is particularly relevant to admixed 
populations, in which substructure increases further the fluidity 
of racial/ethnic labels (Suarez-Kurtz, 2005). Because interethnic 
admixture is either common or increasing at a fast pace in many, 
if not most populations, extrapolation on a global scale of PGx 
data from well-defined ethnic groups is plagued with uncertainty. 
To impact positively on global health, PGx must broaden its scope, 
with respect to both target and population diversity, and be inclu-
sive of admixed populations with their perceived challenges and 
advantages. From this perspective, PGx studies in Brazilians have 
the potential to contribute relevant information towards personal-
ized drug prescription worldwide.
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with increased susceptibility to warfarin, suggests that these two 
Amerindian populations comprise high proportions of individuals 
requiring reduced warfarin doses for appropriate anticoagulation 
in the prevention or treatment of thromboembolism.
studIes In BrazIlIans WIth JaPanese ancestry
Brazil hosts the largest Japanese community outside Japan, esti-
mated at 1.5 million individuals, one third of whom are first-
generation, Brazilian-born with native Japanese parents. This 
large community provided a unique opportunity for compara-
tive studies of the distribution of PGx polymorphisms in native 
Japanese versus their Brazilian-born descendants. In collabora-
tion with Ândrea Ribeiro-dos-Santos et al. (Universidade Federal 
do Pará) and Emilio Moriguchi (Universidade Federal do Rio 
Grande do Sul) we explored this opportunity with respect to 
functional polymorphisms in genes that modulate drug disposi-
tion (CYP2C9, CYP2C19, and GSTM3) or response (VKORC1), 
and that differ significantly in frequency in native Japanese versus 
Brazilians with no Japanese ancestry (Perini et al., 2009). Our 
study detected no difference in the frequency of the CYP2C9*2, 
CYP2C9*3, CYP2C19*2, CYP2C19*3, GSTM3*A/*B, or VKORC1 
3673G > A, 5808T > G, 6853G > C, and 9041G > A polymorphisms 
between native Japanese and first-generation Japanese descend-
ants. In contrast, significant differences in the frequency of each 
polymorphism were observed between native or first-generation 
Japanese and Brazilians with no Japanese ancestry. The striking 
similarity in the frequency of clinically relevant PGx polymor-
phisms between Brazilian-born Japanese descendants and native 
Japanese led us to suggest that the former may be recruited for 
clinical trials designed to generate bridging data for the Japanese 
population in the context of the International Conference on 
Harmonization for drug development.
the BrazIlIan PharmacoGenetIc netWork (refarGen)
To deal with the specificity of PGx in Brazilians, a nation-wide 
network named Rede Nacional de Farmacogenética (Brazilian 
National Pharmacogenetics Network, Refargen) was established 
in 2004 (Suarez-Kurtz, 2004). Presently, the network congregates 18 
research groups from various Brazilian institutions, and its mission 
is to provide leadership in PGx research and education in Brazil, 
with a population health impact. Information on Refargen’s mem-
bers and activities, as well as an updated database of allele, genotype 
and haplotype frequencies of PGx polymorphisms in the Brazilian 
population may be accessed at the network internet site1.
concludInG remarks and PersPectIves
The kaleidoscopic diversity of the admixed Brazilian population, with 
tri-hybrid biogeographical ancestry in Europe, Africa, and America 
adds complexity to, but also creates advantages for PGx research. 
Advantages include the opportunity to explore PGx associations 
in individuals with heterogeneous genetic ancestry, under similar 
environmental and socio-economical  conditions, and to gather 
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